Chinese vaccine company Sinovac Biotech Ltd has teamed up with 69 partner companies to launch the Laifu Initiative, which is aimed at strengthening innovation and resilience across China's biopharmaceutical supply chain.

The initiative was unveiled at Sinovac's recent supply chain ecosystem conference in Beijing. The joint effort reflects a broader shift in China's biopharma sector from traditional supplier-buyer relationships toward deeper, full-chain collaboration. The collaboration will integrate research, production, quality assurance and global market expansion, aligning with China's status as the world's second-largest pharmaceutical market.

"China's biopharma sector must provide a truly global solution to human health," said Yin Weidong, chairman, president and CEO of Sinovac, in his keynote address.

"That means delivering the top-tier science and services to meet emerging health needs, winning international trust through quality, and ensuring products remain affordable and accessible."

The Laifu Initiative outlines four key commitments. It calls for greater openness, encouraging global partners to participate in China's healthcare market while urging Chinese companies to expand abroad. It promotes joint research platforms to accelerate breakthroughs and shorten innovation cycles. It emphasizes full-chain collaboration, integrating R&D, manufacturing, quality control and distribution. Finally, it underscores a balance between maintaining high standards and improving efficiency to achieve cost advantages.

Gao Qiang, chief operating officer of Sinovac, said the company has already put these principles into practice, citing co-development projects and international market expansion achieved with partners.

Executives from leading biotech companies, including Cytiva, Thermo Fisher Scientific and Cobetter, also talked about their cooperation with Sinovac, pointing to both tangible results and opportunities that lie ahead.